How Vitae Pharmaceuticals remains successful in the cash-intensive life sciences market
It takes more than pocket change to find success in the life sciences market and Vitae Pharmaceuticals has it. Jeffrey S. Hatfield, CEO of Vitae, a clinical-stage biopharmaceutical company dedicated to discovering and developing a portfolio of novel, small molecule, best-in-class compounds for important disease areas, discusses the challenges and successes of being a growing biopharmaceutical company in today's market
In this Q&A with Lisa Walkush, principal with Grant Thornton LLP's Life Sciences practice, Hatfield covers,
• How Vitae overcame funding drought and created a self-sustaining financing model.
• What makes employees stay at Vitae when there are larger companies like GlaxoSmithKline and Merck in the area.
• How Vitae uses patient feedback in their drug-development process.
• How to grow an emerging life sciences company.
